Bibliography
- Coles S, Haire K, Kenny T, et al. Monitoring access to nationally commissioned services in England. Orphanet J Rare Dis 2012;7:85
- Stevens A, Colin-Jones D, Gabbay J. “Quick and clean”: authoritative health technology assessment for local health care contracting. Health Trends 1995;27(2):37-42
- Kalydeco NHS statement. Available from: www.cfireland.ie/pdf/Kalydeco_NHS_Statement_19dec.pdf [Accessed 23 October 2014]
- Non cancer drug policy. Available from: www.yhscg.nhs.uk/commissioning/non-cancer-drug-policy.htm [Accessed 4 November 2014]
- Orphan designation. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp [Accessed 4 November 2014]
- Ultra orphan drugs. Available from: http://admin.nice.org.uk/media/065/85/Citizens_Council_Ultraorphan.pdf [Accessed 23 October 2014]
- Lysosomal storage disorders service. Available from: http://webarchive.nationalarchives.gov.uk/20070205105506/http://advisorybodies.doh.gov.uk/nscag/services/lyso.htm [Accessed 4 November 2014]
- Priority access for children during Myozyme supply shortage. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000224.jsp&mid=WC0b01ac058004d5c1 [Accessed 4 November 2014]
- Further supply disruption of genzyme’s Cerezyme and fabrazyme leads EMEA to give new temporary treatment recommendations. Available from: www.thepharmaletter.com/article/further-supply-disruption-of-genzyme-s-cerezyme-and-fabrazyme-leads-emea-to-give-new-temporary-treatment-recommendations-but-no-problems-with-myozyme [Accessed 23 October 2014]
- Ultra orphan drugs. Available from: www.bazian.com/case_studies/NCGUltraOrphanDrugs [Accessed 4 November 2014]
- Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost of enzyme replacement and substrate reduction therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 2012;16(39):1-543
- Nicholl DJ, Hilton-Jones D, Palace J, et al. Open letter to prime minister David Cameron and health secretary Andrew Lansley. BMJ 2010;341:c6466
- Daniels N, Sabin JE. Setting limits fairly. Oxford University Press; Oxford: 2002
- NHS England specialised services. Available from: www.england.nhs.uk/ourwork/commissioning/spec-services [Accessed 23 October 2014]
- Devlin N, Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? Department of economics discussion paper series 03/01. City University; London: 2002
- NICE highly specialised technologies guidance. Available from: www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance [Accessed 23 October 2014]
- Atypical haemolytic uraemic syndrome (aHUS) eculizumab evaluation consultation document 2. Available from: www.nice.org.uk/guidance/gid-atypicalhaemolyticuraemicsyndromeahuseculizumab/documents/atypical-haemolytic-uraemic-syndrome-ahus-eculizumab-evalution-consultation-document-2 [Accessed 23 October 2014]
- Atypical haemolytic uraemic syndrome (aHUS) eculizumab evaluation consultation document. Available from: www.nice.org.uk/guidance/gid-atypicalhaemolyticuraemicsyndromeahuseculizumab/documents/atypical-haemolytic-uraemic-syndrome-ahus-eculizumab-evalution-consultation-document [Accessed 23 October 2014]
- Tappenden P, Alice B, Abdullah P, et al. Eculizumab for treating atypical haemolytic uraemic syndrome. School of health and related research; Sheffield: 2013
- Faria R, et al. Tafamadis for transthyretin familial polyneuropathy (TTR-FAP): Evidence Review Group assessment of manufacturer submission. CRD/CHE Technology Assessment Group, New York: 2013
- Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ 2005;331(7523):1019-21
- Winquist E, Coyle D, Clarke JT, et al. Application of a policy framework for the public funding of drugs for rare diseases. J Gen Intern Med 2014;29(Suppl 3):S774-9
- Available from: www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2014/05/WC500167532.pdf [Accessed 23 October 2014]
- Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf [Accessed 23 October 2014]
- Godfrey J. A new methodology for HTA ultra orphan drugs. Eurordis; Paris: 2012. Available from: download.eurordis.org/ecrd2012/T5S0505_J_GODFREY.pdf
- NICE to assess high cost low volume drugs. Available from: https://www.gov.uk/government/news/nice-to-assess-high-cost-low-volume-drugs [Accessed 23 October 2014]
- European reference networks. Available from: http://ec.europa.eu/health/rare_diseases/european_reference_networks/erf/index_en.htm [Accessed 23 October 2014]
- Department of Health. The Pharmaceutical Price Regulation Scheme 2014. Department of Health; London: 2013
- Department of Health. The Pharmaceutical Price Regulation Scheme 2009. Department of Health; London: 2008